Pregabalin (Lyrica) is a gabapentinoid first-line for fibromyalgia, diabetic neuropathy, postherpetic neuralgia, neuropathic pain associated with spinal cord injury, and as an adjunct for partial-onset seizures. Important nursing assessments and patient teaching: (1) peripheral edema and weight gain — common (sometimes substantial) and may unmask or worsen heart failure; report new lower-extremity edema or sudden weight gain; (2) blurred vision is reported in clinical trials and may resolve or persist; report; (3) CNS — dizziness, somnolence, ataxia, fatigue; older adults at higher fall risk; (4) mood changes and suicidal ideation as a class warning of antiseizure medications; (5) misuse — pregabalin is Schedule V (controlled) because of euphoria potential, especially in patients with substance use disorder history; report early refill requests, dose escalation, lost prescriptions, or concomitant opioid use; (6) renal dose adjustment, gradual taper to discontinue, avoid alcohol and unauthorized CNS depressants; (7) angioedema and serious cutaneous reactions are rare; report facial swelling. Pink urine may be drug-related but is not the priority surveillance, and dry mouth is mild; minor bruise is investigated for fall risk, not Lyrica-specific.
In-depth explanation
Edema/weight, vision, mood, and misuse signs are the must-monitor cluster for pregabalin. Schedule V status is the most distinct point compared with gabapentin.
For study reference only. Always follow current clinical guidelines and your institution’s protocols.